comprehensive -WSS

comprehensive

author：focus 2025-09-28 01:39:46 - browse：76

Aduhelm package — Jessica Rinaldi/The Boston Globe

Biogen is giving up its ownership of Aduhelm, the Alzheimer’s disease treatment whose 2021 approval led to scrutiny and outrage, turning the page on a tempestuous chapter in the company’s long history.

Neurimmune, the Swiss company that invented Aduhelm, will regain full rights to the intravenous medicine, Biogen said Wednesday. Biogen will also terminate an ongoing clinical trial meant to prove the treatment’s benefits for patients in the early stages of Alzheimer’s.

“When searching for new medicines, one breakthrough can be the foundation that triggers future medicines to be developed,” Biogen CEO Christopher Viehbacher said in a statement. “Aduhelm was that groundbreaking discovery that paved the way for a new class of drugs and reinvigorated investments in the field.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： What would happen to your eyes if you looked at the solar eclipse?

WSS

New guidelines on severe brain injury complicate already difficult decisions

Bird flu surveillance in wastewater gets boost from consortium

Addressing health care workers' trauma can help fight burnout

Weight bias in eating disorder treatment complicated by new weight loss drugs

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

Cue Health, Covid

leisure time

comprehensive

leisure time

23andMe had bad news about my health. I wish a person had delivered it

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

After affirmative action ruling, medical educators look to 'holistic review'

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Affirmative action in medical school literally saved lives

The story of mRNA: From a loose idea to a tool that may help curb Covid

BioMarin wins approval for gene therapy to treat hemophilia A

FDA poised to publish guidelines for clinical trial diversity

Medical records are filled with copy

FDA poised to publish guidelines for clinical trial diversity

leisure time

CDC concerned about possible undetected monkeypox spread in U.K.

Listen: More tumult at BIO & coercive care for sickle cell patients

For longer

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Listen: A conversation with researcher Kevin Esvelt on biosecurity

H5N1 virus can be tracked in retail milk, scientists say

knowledge

knowledge

leisure time

focus